Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LC28 0126

Drug Profile

LC28 0126

Alternative Names: LC-280126; NecroX-7

Latest Information Update: 28 Oct 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator LG Life Sciences
  • Developer LG Chem; LG Life Sciences
  • Class Antifibrotics; Cardiovascular therapies; Hepatoprotectants; Indoles; Small molecules; Thiazoles
  • Mechanism of Action NF-kappa B inhibitors; NFATC transcription factor inhibitors; Proto oncogene proteins c fos inhibitors; Reactive oxygen species inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Hepatic fibrosis

Highest Development Phases

  • Phase II Myocardial infarction
  • No development reported Hepatic fibrosis; Pulmonary fibrosis

Most Recent Events

  • 28 Oct 2020 No recent reports of development identified for preclinical development in Pulmonary-fibrosis in South Korea
  • 15 Nov 2017 LG Life Sciences completes a phase I trial in Healthy volunteers in South Korea (NCT03196804)
  • 07 Jun 2017 LG Life Sciences initiates enrolment in a phase I trial in Healthy volunteers in South Korea (NCT03196804)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top